SB14 prohibits pharmaceutical manufacturers from discriminating against 340B-covered entities—such as qualifying healthcare facilities and their partner pharmacies—by denying them access to discounted drug pricing. If a manufacturer offers a drug at a 340B price in any other state, it must do the same in Kentucky.
The Kentucky State Senate passed SB14 on February 13, 2025 by a vote of 33 to 4. We have assigned pluses to the nays because this bill imposes government mandates on private businesses, compelling them to comply with regulations that interfere with their freedom to contract and operate according to their own principles—violating the First Amendment and Article I, Section 10, of the U.S. Constitution. Moreover, the federal 340B drug discount program lacks constitutional authorization under Article I, Section 8. By propping up this federal program at the state level, SB14 further entrenches government interference in healthcare and undermines the free market.
